Kieron Hall

Sygnature Discovery has appointed Kieron Hall as Chief Commercial Officer

Sygnature Discovery has announced the appointment of Kieron Hall as its new Chief Commercial Officer (CCO) and Board member.

Kieron will play a key role in driving Sygnature Discovery’s strategic vision forward. His leadership will be instrumental in steering the group towards its ambitious growth goals and building upon the company’s strong foundation of scientific excellence and customer success.

He will also spearhead the development and implementation of a dynamic go-to-market strategy.

This strategy is designed to leverage the group’s strengths and enhance customer relationships through an even more responsive and scientifically driven commercial organisation.

Commenting on his appointment Kieron said: “I am excited to join Sygnature Discovery at this pivotal time as the organisation readies itself for the next phase of growth.

“Sygnature’s reputation for scientific excellence and unwavering commitment to translating great ideas in drug discovery into clinical candidates truly sets it apart.

“I’m eager to apply my experience in building and leading high-performing teams to drive Sygnature’s vision of becoming the leading global drug discovery CRO.”